<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198822</url>
  </required_header>
  <id_info>
    <org_study_id>GHS-A-00-03-00019-00</org_study_id>
    <nct_id>NCT00198822</nct_id>
  </id_info>
  <brief_title>Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh</brief_title>
  <official_title>Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian International Development Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sight and Life Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Access Business Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether providing women with a weekly oral
      supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a
      recommended intake from early pregnancy through three months postpartum, can reduce the risk
      of maternal mortality, fetal loss, or infant mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal mortality and vitamin A deficiency coexist in rural South Asia. In Nepal, weekly
      supplementation with vitamin A or beta-carotene during the child-bearing years reduced
      all-cause maternal mortality and, in night blind women, also infant mortality. The present
      trial is testing the efficacy of the same supplements from ~9 weeks' gestation to 12 weeks
      postpartum. The planned sample size is 68,000 pregnancies. It is being conducted in 19 rural
      unions, covering an area of ~750 sq km with a population of ~580,000 in Gaibandha and
      Southern Rangpur Districts in Northern Bangladesh. The study area was mapped as 596 &quot;sectors&quot;
      (unit of randomization), each comprising 200-275 households; ~135,000 houses were numerically
      addressed and, at the outset, 103,000 women were listed. Women are visited at home every 5
      weeks by 596 trained female staff to detect pregnancy by a combination of menstrual history
      and urine testing. Newly married women are prospectively enlisted for pregnancy surveillance.
      Following informed consent urine-positive (pregnant) women detected during surveillance are
      enrolled to receive weekly a capsule containing 7000 retinol equivalents of preformed vitamin
      A, 42 mg of beta-carotene or placebo. Vital events are recorded weekly through 3 months
      postpartum. Trained interviewers conduct maternal nutritional and health and household
      socioeconomic assessments in the 1st trimester. At 3 months postpartum, interviewers assess
      both mother and infant for health and nutritional status, including apparent birth defects
      that are later physician-confirmed. An additional home health assessment occurs at 6 months
      post partum, and vital status is recorded for mother and infant at one year postpartum. A ~3%
      subsample of enrolled pregnant women participate in a substudy involving enhanced clinical,
      anthropometric, biochemical, body compositional, morbidity and interview-based assessment
      protocols in the 1st, 2nd and 3rd trimesters, and at 3 months post-partum. Reported maternal
      and infant deaths are verified and causes ascertained during &quot;verbal autopsy&quot; interviews with
      family members of the deceased.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause, Pregnancy-related Mortality</measure>
    <time_frame>Deaths during pregnancy through 12 weeks postpartum</time_frame>
    <description>Mortality evaluated on intent-to-treat basis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause 3-month Infant Mortality</measure>
    <time_frame>Deaths through the 1st 12 weeks of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Morbidity, Including Obstetric Complications</measure>
    <time_frame>through the 1st 24 weeks following termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Birth</measure>
    <time_frame>within 24 weeks after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal Growth and Postnatal Infant Growth Through Three Months of Age</measure>
    <time_frame>through the 1st 12 weeks after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Morbidity Through 3 Months of Age</measure>
    <time_frame>within 24 weeks after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)</measure>
    <time_frame>Third trimester of pregnancy (about the 32nd week of gesatation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)</measure>
    <time_frame>Third trimester of pregnancy (about the 32nd week of gestation)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59666</enrollment>
  <condition>Vitamin A Deficiency</condition>
  <condition>Maternal Mortality</condition>
  <condition>Infant Mortality</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin A or Beta-Carotene Supplements</intervention_name>
    <description>weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Married women of reproductive age

          -  First pregnancy during time period of trial

        Exclusion Criteria:

          -  Premenarchial girls

          -  Married women with a previous pregnancy enrolled into the trial

          -  Previously married women who have moved into the study area

          -  Single women (never married, widowers)

          -  Women who are sterilized (or whose husbands are sterilized)

          -  Menopausal women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith P West, Jr., Dr.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Parul Christian, Dr.P.H.</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf DW Klemm, Dr.P.H.</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahbubur Rashid, MBBS, MSc</last_name>
    <role>Study Director</role>
    <affiliation>JiVitA Bangladesh Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain B Labrique, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfred Sommer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JiVitA Bangladesh Project</name>
      <address>
        <city>Rangpur</city>
        <state>Rajshahi Division</state>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JiVitA Project Office</name>
      <address>
        <city>Rangpur</city>
        <state>Rangpur District</state>
        <zip>5400</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jhsph.edu/chn/Research/micronutrients.html</url>
    <description>Micronutrient research at the Center for Human Nutrition at Johns Hopkins Bloomberg School of Public Health</description>
  </link>
  <reference>
    <citation>West KP Jr, Katz J, Khatry SK, LeClerq SC, Pradhan EK, Shrestha SR, Connor PB, Dali SM, Christian P, Pokhrel RP, Sommer A. Double blind, cluster randomised trial of low dose supplementation with vitamin A or beta carotene on mortality related to pregnancy in Nepal. The NNIPS-2 Study Group. BMJ. 1999 Feb 27;318(7183):570-5.</citation>
    <PMID>10037634</PMID>
  </reference>
  <reference>
    <citation>Katz J, West KP Jr, Khatry SK, Pradhan EK, LeClerq SC, Christian P, Wu LS, Adhikari RK, Shrestha SR, Sommer A. Maternal low-dose vitamin A or beta-carotene supplementation has no effect on fetal loss and early infant mortality: a randomized cluster trial in Nepal. Am J Clin Nutr. 2000 Jun;71(6):1570-6.</citation>
    <PMID>10837300</PMID>
  </reference>
  <reference>
    <citation>Christian P, West KP Jr, Khatry SK, LeClerq SC, Kimbrough-Pradhan E, Katz J, Shrestha SR. Maternal night blindness increases risk of mortality in the first 6 months of life among infants in Nepal. J Nutr. 2001 May;131(5):1510-2.</citation>
    <PMID>11340108</PMID>
  </reference>
  <reference>
    <citation>Christian P, West KP Jr, Khatry SK, Katz J, LeClerq SC, Kimbrough-Pradhan E, Dali SM, Shrestha SR. Vitamin A or beta-carotene supplementation reduces symptoms of illness in pregnant and lactating Nepali women. J Nutr. 2000 Nov;130(11):2675-82.</citation>
    <PMID>11053506</PMID>
  </reference>
  <reference>
    <citation>Christian P, West KP Jr, Khatry SK, Kimbrough-Pradhan E, LeClerq SC, Katz J, Shrestha SR, Dali SM, Sommer A. Night blindness during pregnancy and subsequent mortality among women in Nepal: effects of vitamin A and beta-carotene supplementation. Am J Epidemiol. 2000 Sep 15;152(6):542-7.</citation>
    <PMID>10997544</PMID>
  </reference>
  <reference>
    <citation>West KP Jr. Extent of vitamin A deficiency among preschool children and women of reproductive age. J Nutr. 2002 Sep;132(9 Suppl):2857S-2866S. doi: 10.1093/jn/132.9.2857S. Erratum in: J Nutr 2002 Nov;132(11):3432.</citation>
    <PMID>12221262</PMID>
  </reference>
  <results_reference>
    <citation>West KP Jr, Christian P, Labrique AB, Rashid M, Shamim AA, Klemm RD, Massie AB, Mehra S, Schulze KJ, Ali H, Ullah B, Wu LS, Katz J, Banu H, Akhter HH, Sommer A. Effects of vitamin A or beta carotene supplementation on pregnancy-related mortality and infant mortality in rural Bangladesh: a cluster randomized trial. JAMA. 2011 May 18;305(19):1986-95. doi: 10.1001/jama.2011.656.</citation>
    <PMID>21586714</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrique AB, Christian P, Klemm RD, Rashid M, Shamim AA, Massie A, Schulze K, Hackman A, West KP Jr. A cluster-randomized, placebo-controlled, maternal vitamin A or beta-carotene supplementation trial in Bangladesh: design and methods. Trials. 2011 Apr 21;12:102. doi: 10.1186/1745-6215-12-102.</citation>
    <PMID>21510905</PMID>
  </results_reference>
  <results_reference>
    <citation>Gunnsteinsson S, Labrique AB, West KP Jr, Christian P, Mehra S, Shamim AA, Rashid M, Katz J, Klemm RD. Constructing indices of rural living standards in Northwestern Bangladesh. J Health Popul Nutr. 2010 Oct;28(5):509-19.</citation>
    <PMID>20941903</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>September 1, 2011</results_first_submitted>
  <results_first_submitted_qc>September 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2011</results_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Keith P. West</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Maternal mortality</keyword>
  <keyword>Infant mortality</keyword>
  <keyword>Vitamin A</keyword>
  <keyword>Beta-carotene</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Bangladesh</keyword>
  <keyword>Neonatal mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A Deficiency</mesh_term>
    <mesh_term>Night Blindness</mesh_term>
    <mesh_term>Infant Death</mesh_term>
    <mesh_term>Maternal Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Beta Carotene</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
    <mesh_term>Carotenoids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women were recruited into the trial from August 2001 to January 2007. As this was a community trial, we identified pregnant women by conducting a urine test on women reporting to be amenstrual from the last visit during 5 weekly visit cycles to their homes in rural communities of the districts of Rangpur and Gaibandha, Bangladesh.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Placebo Control</title>
          <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="P2">
          <title>2 Vitamin A Supplement</title>
          <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="P3">
          <title>3 Beta-Carotene Group</title>
          <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19876">No. of consenting pregnant women in the placebo arm of trial cohort</participants>
                <participants group_id="P2" count="19826">No. of consenting pregnant women in the vitamin A arm of trial cohort</participants>
                <participants group_id="P3" count="20019">No. of consenting pregnant women in the beta-catorene arm of trial cohort</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19862">No. of consented pregnant women in placebo arm with vital status known at 12 weeks postpartum</participants>
                <participants group_id="P2" count="19806">No. of consented pregnant women in vitamin A arm with vital status known at 12 weeks postpartum</participants>
                <participants group_id="P3" count="19998">No. of consented pregnant women in beta-catorene arm with vital status known at 12 weeks postpartum</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Placebo Control</title>
          <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="B2">
          <title>2 Vitamin A Supplement</title>
          <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="B3">
          <title>3 Beta-Carotene Group</title>
          <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19862"/>
            <count group_id="B2" value="19806"/>
            <count group_id="B3" value="19998"/>
            <count group_id="B4" value="59666"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>A very small number of women in the study were unable to recollect or even work out their age. In rural South Asia, this is not uncommon and of the 35 women for whom we do not have an age, 14 are in the placebo group, 15 in the Vitamin A group and 6 in the beta-carotene group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5875"/>
                    <measurement group_id="B2" value="5774"/>
                    <measurement group_id="B3" value="5936"/>
                    <measurement group_id="B4" value="17585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13973"/>
                    <measurement group_id="B2" value="14017"/>
                    <measurement group_id="B3" value="14056"/>
                    <measurement group_id="B4" value="42046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>A very small number of women in the study were unable to recollect or even work out their age. In rural South Asia, this is not uncommon and of the 35 women for whom we do not have an age, 14 are in the placebo group, 15 in the Vitamin A group and 6 in the beta-carotene group.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.03" spread="6.53"/>
                    <measurement group_id="B2" value="23.17" spread="6.56"/>
                    <measurement group_id="B3" value="23.06" spread="6.56"/>
                    <measurement group_id="B4" value="23.09" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19862"/>
                    <measurement group_id="B2" value="19806"/>
                    <measurement group_id="B3" value="19998"/>
                    <measurement group_id="B4" value="59666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bangladesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19862"/>
                    <measurement group_id="B2" value="19806"/>
                    <measurement group_id="B3" value="19998"/>
                    <measurement group_id="B4" value="59666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>All-cause 3-month Infant Mortality</title>
        <time_frame>Deaths through the 1st 12 weeks of life</time_frame>
        <population>Mortality evaluated on intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo Control</title>
            <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O2">
            <title>2 Vitamin A Supplement</title>
            <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O3">
            <title>3 Beta-Carotene Group</title>
            <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause 3-month Infant Mortality</title>
          <population>Mortality evaluated on intent-to-treat basis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13965"/>
                <count group_id="O2" value="13898"/>
                <count group_id="O3" value="14018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951"/>
                    <measurement group_id="O2" value="904"/>
                    <measurement group_id="O3" value="979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Morbidity, Including Obstetric Complications</title>
        <time_frame>through the 1st 24 weeks following termination of pregnancy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Birth</title>
        <time_frame>within 24 weeks after birth</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal Growth and Postnatal Infant Growth Through Three Months of Age</title>
        <time_frame>through the 1st 12 weeks after birth</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Morbidity Through 3 Months of Age</title>
        <time_frame>within 24 weeks after birth</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)</title>
        <time_frame>Third trimester of pregnancy (about the 32nd week of gesatation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo Control</title>
            <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O2">
            <title>2 Vitamin A Supplement</title>
            <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O3">
            <title>3 Beta-Carotene Group</title>
            <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)</title>
          <units>Plasma beta-carotene micromoles / liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="367"/>
                <count group_id="O3" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.09"/>
                    <measurement group_id="O2" value="0.12" spread="0.12"/>
                    <measurement group_id="O3" value="0.12" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All-cause, Pregnancy-related Mortality</title>
        <description>Mortality evaluated on intent-to-treat basis</description>
        <time_frame>Deaths during pregnancy through 12 weeks postpartum</time_frame>
        <population>As the study ended on the advice of the Data and Safety Monitoring Board, based on evidence of no difference, all enrolled women who had a chance of being followed through 84 days after the end of their pregnancy were included in the trial. The cohort included pregnancies identified between August 17, 2001 and January 5, 2006.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo Control</title>
            <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O2">
            <title>2 Vitamin A Supplement</title>
            <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O3">
            <title>3 Beta-Carotene Group</title>
            <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause, Pregnancy-related Mortality</title>
          <description>Mortality evaluated on intent-to-treat basis</description>
          <population>As the study ended on the advice of the Data and Safety Monitoring Board, based on evidence of no difference, all enrolled women who had a chance of being followed through 84 days after the end of their pregnancy were included in the trial. The cohort included pregnancies identified between August 17, 2001 and January 5, 2006.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19862"/>
                <count group_id="O2" value="19806"/>
                <count group_id="O3" value="19998"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size was based on an expected placebo group MR of 600/100,000 pregnancies, requiring 18,000 pregnancies to detect a 35% reduction in all-cause mortality, with a 5% type I error, 80% power, 1.21 design effect, 15% early pregnancy loss and 10% loss to follow-up. A mid-study DSMB analysis suggested a lower MR, leading the SS to be increased to 67,740. However, with no mortality difference evident at a DSMB meeting in Dec 2006, the trial was halted leaving 59,721 in the trial cohort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>We set an a priori level of statistical significance of p equal to 0.05.</p_value_desc>
            <method>generalized estimating equations</method>
            <method_desc>RR with 95% CIs were estimated by GEE binomial regression, with a log link function and exchangeable correlation appropriate for binary data.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>The vitamin A group and the Beta-carotene group were compared to the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)</title>
        <time_frame>Third trimester of pregnancy (about the 32nd week of gestation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo Control</title>
            <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O2">
            <title>2 Vitamin A Supplement</title>
            <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
          <group group_id="O3">
            <title>3 Beta-Carotene Group</title>
            <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)</title>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="367"/>
                <count group_id="O3" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.31"/>
                    <measurement group_id="O2" value="1.25" spread="0.33"/>
                    <measurement group_id="O3" value="1.06" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Placebo Control</title>
          <description>Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="E2">
          <title>2 Vitamin A Supplement</title>
          <description>Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
        <group group_id="E3">
          <title>3 Beta-Carotene Group</title>
          <description>Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Keith P West, Jr., Principal Investigator</name_or_title>
      <organization>Center for Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of Public Health</organization>
      <phone>410-955-2061</phone>
      <email>kwest@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

